The estimated Net Worth of Ashish M Sagrolikar is at least $4.79 Milion dollars as of 2 July 2021. Mr. Sagrolikar owns over 3,500 units of Zogenix Inc stock worth over $460,470 and over the last 6 years he sold ZGNX stock worth over $0. In addition, he makes $4,326,180 as Executive Vice President a Chief Commercial Officer at Zogenix Inc.
Ashish has made over 5 trades of the Zogenix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,500 units of ZGNX stock worth $93,380 on 2 July 2021.
The largest trade he's ever made was exercising 4,531 units of Zogenix Inc stock on 15 March 2021 worth over $120,887. On average, Ashish trades about 1,234 units every 40 days since 2018. As of 2 July 2021 he still owns at least 17,259 units of Zogenix Inc stock.
You can see the complete history of Mr. Sagrolikar stock trades at the bottom of the page.
Ashish M. Sagrolikar serves as Executive Vice President, Chief Commercial Officer of the Company. Mr. Sagrolikar has served as our Executive Vice President and Chief Commercial Officer since July 2018. Mr. Sagrolikar has over twenty five years of global pharmaceutical sales, marketing and operations experience. Mr. Sagrolikar previously served as Vice President, Marketing at GlaxoSmithKline plc from April 2014 through June 2018 after joining GlaxoSmithKline plc as Commercial Leader, Rare Diseases in June 2013. From November 2009 through June 2013, Mr. Sagrolikar served in various sales, marketing and business development roles at Baxter International Inc. Mr. Sagrolikar earned his MBA at the Institute of Management Development (IMD) in Lausanne, Switzerland, in 2000, and a Bachelor of Pharmacy from the Government College of Pharmacy, Karad, India, in 1987.
As the Executive Vice President a Chief Commercial Officer of Zogenix Inc, the total compensation of Ashish Sagrolikar at Zogenix Inc is $4,326,180. There are 4 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
Ashish Sagrolikar is 53, he's been the Executive Vice President a Chief Commercial Officer of Zogenix Inc since 2018. There are 16 older and 3 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Ashish's mailing address filed with the SEC is 5858 Horton St #455, Emeryville, CA 94608, USA.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo a Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: